You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output.
Click here to find out more.
X Demographics
Mendeley readers
Attention Score in Context
| Title |
Upstream solutions for price-gouging on critical generic medicines
|
|---|---|
| Published in |
Journal of Pharmaceutical Policy and Practice, May 2016
|
| DOI | 10.1186/s40545-016-0064-8 |
| Pubmed ID | |
| Authors |
Adam R. Houston, Reed F. Beall, Amir Attaran |
| Abstract |
Exorbitant price increases for critical off-patent medicines have received considerable media attention in recent months, leading to an investigation by the U.S. Senate. However, much of this attention has focused upon the companies that initiated the price increases, all of whom had recently acquired the drugs in question. Overlooked are upstream interventions with the originators of these drugs to prevent generics trolling in the first place. Using the particular example of Eli Lilly and Company's efforts to divest itself of cycloserine, a flawed process that paved the way for the recent price hike by Rodelis Therapeutics, this article highlights the responsibilities of drug originators, and safeguards to ensure similar rights transfers do not affect ongoing affordable access. |
X Demographics
The data shown below were collected from the profiles of 4 X users who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Canada | 2 | 50% |
| United States | 1 | 25% |
| Unknown | 1 | 25% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Members of the public | 2 | 50% |
| Scientists | 1 | 25% |
| Practitioners (doctors, other healthcare professionals) | 1 | 25% |
Mendeley readers
The data shown below were compiled from readership statistics for 26 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 26 | 100% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Researcher | 6 | 23% |
| Student > Bachelor | 4 | 15% |
| Student > Ph. D. Student | 3 | 12% |
| Student > Master | 3 | 12% |
| Student > Doctoral Student | 2 | 8% |
| Other | 2 | 8% |
| Unknown | 6 | 23% |
| Readers by discipline | Count | As % |
|---|---|---|
| Pharmacology, Toxicology and Pharmaceutical Science | 6 | 23% |
| Economics, Econometrics and Finance | 5 | 19% |
| Medicine and Dentistry | 4 | 15% |
| Biochemistry, Genetics and Molecular Biology | 1 | 4% |
| Social Sciences | 1 | 4% |
| Other | 3 | 12% |
| Unknown | 6 | 23% |
Attention Score in Context
This research output has an Altmetric Attention Score of 13. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 21 December 2017.
All research outputs
#2,402,552
of 23,206,358 outputs
Outputs from Journal of Pharmaceutical Policy and Practice
#64
of 418 outputs
Outputs of similar age
#40,288
of 299,192 outputs
Outputs of similar age from Journal of Pharmaceutical Policy and Practice
#3
of 9 outputs
Altmetric has tracked 23,206,358 research outputs across all sources so far. Compared to these this one has done well and is in the 89th percentile: it's in the top 25% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 418 research outputs from this source. They typically receive a lot more attention than average, with a mean Attention Score of 11.1. This one has done well, scoring higher than 84% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 299,192 tracked outputs that were published within six weeks on either side of this one in any source. This one has done well, scoring higher than 86% of its contemporaries.
We're also able to compare this research output to 9 others from the same source and published within six weeks on either side of this one. This one has scored higher than 6 of them.